L
Lin Wu
Researcher at Hoffmann-La Roche
Publications - 32
Citations - 3773
Lin Wu is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Diffuse large B-cell lymphoma & CHOP. The author has an hindex of 18, co-authored 26 publications receiving 3398 citations.
Papers
More filters
Journal ArticleDOI
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu,Zijun Y. Xu-Monette,Alexander Tzankov,Tina Green,Lin Wu,Aarthi Balasubramanyam,Wei-Min Liu,Carlo Visco,Yong Li,Roberto N. Miranda,Santiago Montes-Moreno,Karen Dybkær,April Chiu,Attilio Orazi,Youli Zu,Govind Bhagat,Kristy L. Richards,Eric D. Hsi,William W.L. Choi,Xiaoying Zhao,J. Han van Krieken,Qin Huang,Jooryung Huh,Weiyun Z. Ai,Maurilio Ponzoni,Andrés J.M. Ferreri,Fan Zhou,Graham W. Slack,Randy D. Gascoyne,Meifeng Tu,Daina Variakojis,Weina Chen,Ronald S. Go,Miguel A. Piris,Michael Boe Møller,L. Jeffrey Medeiros,Ken H. Young +36 more
TL;DR: It is concluded that MYC/BCL2 coexpression in DLBCL is associated with an aggressive clinical course, is more common in the ABC subtype, and contributes to the overall inferior prognosis of patients with ABC-DLBCL.
Journal ArticleDOI
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
Arthur P. Grollman,Shinya Shibutani,Masaaki Moriya,Frederick W. Miller,Lin Wu,Ute M. Moll,Naomi Suzuki,Andrea Fernandes,Thomas A. Rosenquist,Zvonimir Medverec,Krunoslav Jakovina,Branko Brdar,Neda Slade,Robert J. Turesky,Goodenough Angela,Robert Rieger,Mato Vukelić,Bojan Jelaković +17 more
TL;DR: The experiments test the hypothesis that chronic dietary poisoning by aristolochic acid is responsible for EN and its associated urothelial cancer and conclude that dietary exposure to AA is a significant risk factor for ENand its attendant transitional cell cancer.
Journal ArticleDOI
Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial
Stephan Stilgenbauer,Andrea Schnaiter,Peter Paschka,Thorsten Zenz,Thorsten Zenz,Marianna Rossi,Konstanze Döhner,Andreas Bühler,Sebastian Böttcher,Matthias Ritgen,Michael Kneba,Dirk Winkler,Eugen Tausch,Patrick Hoth,Jennifer Edelmann,Daniel Mertens,Daniel Mertens,Lars Bullinger,Manuela Bergmann,Sabrina Kless,Silja Mack,Ulrich Jäger,Nancy Patten,Lin Wu,Michael Wenger,Günter Fingerle-Rowson,Günter Fingerle-Rowson,Peter Lichter,Mario Cazzola,Clemens M. Wendtner,A. M. Fink,Kirsten Fischer,Raymonde Busch,Michael Hallek,Hartmut Döhner +34 more
TL;DR: Predictive marker analysis identified an interaction of NOTCH1 mutational status and treatment in that rituximab failed to improve response and survival in patients with NotCH1(mut).
Journal ArticleDOI
Aristolochic acid-associated urothelial cancer in Taiwan
Chung-Hsin Chen,Kathleen G. Dickman,Masaaki Moriya,Jiri Zavadil,Viktoriya S. Sidorenko,Karen L. Edwards,Dmitri V. Gnatenko,Lin Wu,Robert J. Turesky,Xue-Ru Wu,Yeong-Shiau Pu,Arthur P. Grollman +11 more
TL;DR: It is concluded that exposure to aristolochic acid contributes significantly to the incidence of UUC in Taiwan, a finding with significant implications for global public health.
Journal ArticleDOI
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study
Carlo Visco,Yong Li,Zijun Y. Xu-Monette,Roberto N. Miranda,Tina Green,Alexandar Tzankov,Wanqing Wen,W-m Liu,Brad S. Kahl,Emanuele S.G. d'Amore,Santiago Montes-Moreno,Karen Dybkær,A Chiu,Wayne Tam,Attilio Orazi,Youli Zu,Govind Bhagat,Jane N. Winter,H-Y Wang,Stacey S O'Neill,Cherie H. Dunphy,Eric D. Hsi,Xianfeng Frank Zhao,Ronald S. Go,William W.L. Choi,Feng Zhou,Magdalena Czader,J. Tong,Xiaoying Zhao,J.H.J.M. van Krieken,Qin Huang,Weiyun Z. Ai,Joan E. Etzell,M. Ponzoni,Anna Ferreri,M A Piris,Michael Boe Møller,C. E. Bueso-Ramos,L J Medeiros,Lin Wu,Ken H. Young +40 more
TL;DR: An algorithm based on the expression of CD10, FOXP1 and BCL6 was developed that had a simpler structure than other recently proposed algorithms and 92.6% concordance with GEP and effectively predicts prognosis of DLBCL patients matching GEP subgroups in the era of rituximab therapy.